A Study of a Blood Marker in Newborns With Brain Injury Caused by Lack of Oxygen at Birth
NCT ID: NCT07292220
Last Updated: 2025-12-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
20 participants
OBSERVATIONAL
2025-12-15
2026-08-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Neurofilament light chain (NfL) is a protein found within the cytoskeletal structure of myelinated axons. When axonal injury occurs, NfL is released into the interstitial space and subsequently enters the cerebrospinal fluid and systemic circulation, where it can be measured. Increased NfL levels have been identified in a variety of neurological conditions, including neurodegenerative disorders and traumatic brain injury. Recent findings show that both cerebrospinal fluid and serum/plasma NfL levels are elevated in newborns diagnosed with HIE, supporting its potential role as a biochemical marker of axonal injury.
The primary aim of this study is to investigate the time-dependent changes in serum NfL levels in newborns diagnosed with HIE and undergoing therapeutic hypothermia, and to evaluate the relationship between these changes, clinical findings, and neuroimaging results. For this purpose, serum NfL levels were measured at four specific time points: within the first six hours after birth (preferably cord blood), upon reaching the target cooling temperature (approximately 12-24 hours), during the rewarming phase (72-96 hours), and on the day of magnetic resonance imaging (preferably day seven). The results are expected to provide insights into the prognostic utility of NfL in HIE and contribute to determining the optimal timing for clinical sampling.
The secondary objective of the study is to compare NfL levels of newborns diagnosed with HIE to those of a control group without HIE, thereby identifying potential cut-off values that may help distinguish between affected and unaffected infants.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Neurofilament light chain (NfL), a myelinated axon-specific structural protein released into the bloodstream following central nervous system injury, has gained increasing attention as a potential biomarker. Neurofilaments are abundant within axons and play a crucial role in radial growth during development, maintenance of axon caliber, and electrical signal conduction. They are intermediate filaments with a diameter of approximately 10 nm and are composed of four major subunits within the central nervous system: heavy, medium, and light neurofilament polypeptides, along with α-internexin.
In various pathological conditions, neurofilaments may accumulate in large quantities within neuronal cell bodies and proximal axons. Such accumulations are characteristic lesions in several neurological disorders, including motor neuron diseases, hereditary neuropathies, neurofilament inclusion disorders, giant axonal neuropathies, metabolic neuropathies, and degenerative motor neuron conditions. Although NfL levels are typically higher in cerebrospinal fluid than in blood, serum or plasma measurements are clinically advantageous due to their minimally invasive nature, reproducibility, and practical applicability. Accordingly, NfL has been widely investigated as a biomarker in both cerebrospinal fluid and blood for a range of neurodegenerative and neurological diseases.
In the neonatal population, clinical investigations have largely focused on HIE, where serum and plasma NfL levels have been associated with disease severity and long-term neurodevelopmental outcomes. Beyond HIE, NfL also shows potential prognostic value in preterm-related morbidities such as intraventricular hemorrhage, periventricular leukomalacia, and diffuse white matter injury. Moreover, its use is being explored as a biochemical indicator of perioperative neurological injury in infants undergoing cardiopulmonary bypass for congenital heart disease, as well as in neonatal sepsis and sepsis-associated encephalopathy.
Recent research has demonstrated significant associations between NfL levels and both magnetic resonance imaging findings and long-term neurodevelopmental outcomes in newborns with HIE treated with therapeutic hypothermia. These observations support the potential of NfL as a biomarker reflecting axonal injury and as a prognostic indicator. However, the number of studies that systematically compare NfL levels at different sampling time points remains limited, emphasizing the need to determine the optimal timing of measurement and to standardize its use in clinical practice.
The primary objective of this study is to measure NfL levels in blood samples obtained at defined time intervals after birth in order to assess the timing and extent of brain involvement. This will support early prognostic evaluation and contribute to the development of future diagnostic algorithms. The secondary objective is to compare infants diagnosed with HIE to a control group, thereby clarifying the extent of brain injury associated with HIE in the neonatal period.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
case
control case
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Diagnosis of hypoxic ischemic encephalopathy (HIE) based on clinical and/or laboratory findings
3. Diagnosis of stage I, stage II, or stage III HIE according to the Sarnat staging system
4. Therapeutic hypothermia (TH) treatment initiated within the first 6 hours after birth
5. Written consent obtained from the legal parent(s) for participation in the study
Exclusion Criteria
2. Newborns with suspected sepsis, metabolic disease, or other systemic disease
3. Premature infants with a gestational age \<36 weeks
4. Therapeutic hypothermia treatment not started on time or inadequately administered
5. Medical conditions preventing blood sampling (e.g., severe coagulopathy, circulatory instability)
0 Days
28 Days
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mustafa Gürkan
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mustafa Gürkan
assistant doctor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
, Kirikkale University, Department of Pediatrics, Kirikkale
Kırıkkale, Yahşihan, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Ümit Ayşe Tandırcıpğlu
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Stull JW, Brown WH, Whiting FM. Some characteristics of metabolism of organochlorine compounds in the bovine. Fed Proc. 1973 Sep;32(9):1995-2002. No abstract available.
Shah DK, Ponnusamy V, Evanson J, Kapellou O, Ekitzidou G, Gupta N, Clarke P, Michael-Titus AT, Yip PK. Raised Plasma Neurofilament Light Protein Levels Are Associated with Abnormal MRI Outcomes in Newborns Undergoing Therapeutic Hypothermia. Front Neurol. 2018 Mar 5;9:86. doi: 10.3389/fneur.2018.00086. eCollection 2018.
Depoorter A, Neumann RP, Barro C, Fisch U, Weber P, Kuhle J, Wellmann S. Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury. Front Neurol. 2018 Nov 20;9:984. doi: 10.3389/fneur.2018.00984. eCollection 2018.
Kyng KJ, Wellmann S, Lehnerer V, Hansen LH, Kuhle J, Henriksen TB. Neurofilament Light Chain serum levels after Hypoxia-Ischemia in a newborn piglet model. Front Pediatr. 2023 Jan 9;10:1068380. doi: 10.3389/fped.2022.1068380. eCollection 2022.
Rutherford M, Ramenghi LA, Edwards AD, Brocklehurst P, Halliday H, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D. Assessment of brain tissue injury after moderate hypothermia in neonates with hypoxic-ischaemic encephalopathy: a nested substudy of a randomised controlled trial. Lancet Neurol. 2010 Jan;9(1):39-45. doi: 10.1016/S1474-4422(09)70295-9. Epub 2009 Nov 5.
Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of neonatal encephalopathy and hypoxic-ischaemic encephalopathy. Early Hum Dev. 2010 Jun;86(6):329-38. doi: 10.1016/j.earlhumdev.2010.05.010. Epub 2010 Jun 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
kırıkkale medical university
Identifier Type: -
Identifier Source: org_study_id